The American College of Cardiology and ADA recommend SGLT2 inhibitors in patients with type 2 diabetes and established ASCVD, regardless of the patient's hemoglobin A1c. SGLT2 inhibitors have been demonstrated to significantly reduce the risk for major adverse cardiovascular events, cardiovascular mortality, heart failure, and CKD. In the EMPEROR-Reduced Clinical trial, empagliflozin was shown to reduce the risk for cardiovascular death and decline in GFR. This was later shown to be a class effect through the 2017 CANVAS trial; individuals who received canagliflozin experienced a 30% reduction in the risk for heart failure hospitalizations, cardiovascular death, and end-stage kidney disease.
Although GLP-1 RA has shown greater efficacy at glucose lowering compared with SGLT2 inhibitors, it is currently recommended for patients without albuminuria, heart failure, or CVD.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Management - Medscape - Apr 27, 2022.
Comments